Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Pharm 2 > The betes > Flashcards

The betes Flashcards

1
Q

Type 1 diabetes vs Type 2 diabetes

A

1:
-5-10% of adutls (peak age 13/14)
-AI destruction of pancreatic beta cells leading to insulin deficiency
-DKA can be initial presentation
–fast breathing (Kussmaul)
–fruity breath
–HA, NV, tired, dry skin and mouth

2:
-MC, >90% adults
-hyperglycemia due to progressive loss of insulin secretion from beta cell superimposed with insulin resistance
-polyuria, polydipsia, nocturia, blurred vision, weight loss

C peptides to see if type 1 or 2
<0.3-0.6 is type 1
>0.3-0.6 Type 2

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

American diabetes association criteria for diag

A
  1. A1C >= 6.5%
  2. Fasting BG>= 126 mg/dl
  3. 2 hour plasma glucose >= 200 mg/dl during an OGTT
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Non pharm therapy

A
  1. Medical nutrition therapy- carb counting
  2. Weight loss or maintenance
  3. Physical activity
  4. Diabetes self management education and support
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Pharm therapy overview of DM

A
  1. Sulfonylureas
  2. Glucosidase inhibitor
  3. Biguanide
  4. Thiazolidenedione
  5. Incretin mimetics- DPP- inhibitors, GLP-1 agonist
  6. SGLT2 inhibitors
  7. Alpha-glucosidase inhibitors
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Goals of therapy

A
  1. Achieve OPTIMAL GLYCEMIC CONTROL- base on age, comorb, pt preference
  2. Reduce the onset & progression of DIABETES RELATED COMPLICATIONS
  3. Minimize microvascular complications= NEUROPATHY, RETINOPATHY, NEPHROPATHY
  4. Aggressively address CV RISK FACTORS= LEAD TO CERTAIN PROTECTIVE MEDS
  5. improve QUALITY OF LIFE
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Biguanides

A

Metformin- 1ST LINE IN T2DM- reduces A1C by 1.5-2.0%
MOA: Activates AMP kinase -> decreases hepatic glucose production-> partial enhances insulin sensitivity in peripheral tissues= NO DIRECT ACTION ON BETA CELLS
TAKE WITH FOOD
SE: GI- n/v/d
RARE: LACTIC ACIDOSIS IN SEVERE ILLNESS
DONT USE IN GFR <30 OR VITAMIN B12 DEFICIENCY

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Sulfonylureas

A

2nd mc prescribed- 1.5-2.0% decrease
NOT FOOD DEPENDENT
1st gen: low potency, high ae
-chlorpropamide, tolazamide, tolbutamide
2nd gen: GLYBURIDE, GLIPIZIDE, GLIMEPIRIDE
MOA: enhances insulin secretion by binding to specific sulfonylurea receptor (SURI) ON BETA CELLS + NOT FOOD DEPENDENT= membrane voltage channel-> insulin release= IMMED RELEASE OF INSULIN REGARDLESS OF GLUCOSE
SE: HYPOGLYCEMIA and weight gain

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Thiazolidinediones

A

2/3rd line: Pioglitazone and Rosiglitazone - 1-1.5%
MOA: bind to peroxisome proliferator activator receptor gamma (PPAR-gamma)= enhances insulin sens @ muscle, live, and fat tissues= glucose and lipid metabolism
MAY TAKE 3-4 MONTHS TO SEE EFFECT
AE: edema, NEW OR WORSENING HEART FAILURE, weight gain, bone fractures, and bladder cancer- BC WORKS IN PERIPHERY

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Glucagon-Like Peptide-1 Receptor Agonists

A

Ozempic, Trulicity, Wegouy, Mounjaro= SQ
3-6 hours= Short acting around food
10-12 hours= long acting without food
MOA: mimics action of GLP-1 stimulate insulin secretion from the Beta cells in glucose dependent manner works on
1. Pancreas- increase insulin release and decrease glucagon
2. Hypothalamus- decrease appetite (CROSSES BBB)
3. Stomach- slow gastric emptying
not 1st line=Combo or monotherapy-> EXCEPT W/ DPP-4 bc work in same sense
AE: NVD, injxn sit rxn
RARE: ACUTE PANCREATITIS, HIGER RISK CARCINOMA AND MEN TYPE 2
PE: injection instructions- thigh/abdomen, rotate sites

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Dipeptidyl Peptidase-4 inhibitors

A

2nd/3rd line: Sitagliptin, saxagliptin, linagliptin, alogliptin- 0.5-1.0%
MOA: inhibit DPP-4 enzyme responsible for degradation of GLP-1 and GIP (gastric inhibitory polypeptide)
AE: stuffy, runny nose, HA, URI -> less n/v than GLP1 bc not interact w/ stomach lining as much
Rare: HEART FAILURE, PANCREATITIS, SJS, joint pain

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Sodium-Glucose Cotransporter-2 Inhibitors

A

2nd line/combo: Jardiance; canagliflozin, dapagliflozin, empagliflozin, ertugliflozin- 0.5-1%
MOA: reduce plasma glucose by preventing kidnyes from reabsorbing glucose back in bloodstream leading to glucose excretion in the urine
CONTRAIN FOR GFR<45
benefit: weightloss bc water loss
SE: hypotn, genitalia fungal infxn/UTI bc of loose glucose out, Euglycemic DKA= normal bs but DKA, DEHYDRATION AND YEAST INFXN
Rare: Amputations, fractures, Fournier gangrene

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

alpha- glucosidase inhibitors

A

Acarbose and Miglitol
MOA: competitively inhibit maltase, isomaltase, sucrase, and glucoamylase in the SI, delaying breakdown of sucrose and complex carbs
SE: flatulence, abdominal pain, diarrhea
Alt option= not in ADA tx algorithm

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Overview

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Insulin

A

DOC FOR GESTATIONAL DIABETES
Insulin-prep for insulin peptide and manufactured through recombinant DNA
Advantage: achieve wide range of glucose targets and dose can be individualized based on glycemic levels
Disadvantages: risk of hypoglycemia, wt gain, injxn burden
Abdomen most consistent absorption

Type 1= Insulin
Type 2= w/ time will need

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Basal Insulin

A

BACKGROUND INSULIN- long acting
Most convenient- Initial insulin formulation in T2DM
options: NPH, detemir, glargine U-100, glargine U-300, degludec U-100, degludec U-200
se:
-Hypoglycemic-> nocturnal hypoglycemia
-less glucose availability
-cost

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Bolus insulin

A

MEAL TIME INSULIN- Short or rapid acting insulins
Rapid: aspart, lispro, glulisine
Ultra rapid: inhaled human insulin or fast acting insulin aspart (Fiasp)
MIMIC PRANDIAL ENDOGENOUS INSULIN RELEASE
PRIOR TO MEAL TIME BUT ONSET MATTERS

17
Q

Other insulins

A
  1. U-500
    -for extreme insulin resistance
  2. Pre-mixed insulin products= basal and prandial component
    -fewer injxns but hard to tailor to pt
  3. Inhaled insulin
    -se: cough and URI
18
Q

Type 1 DM

A
  1. Lifestyle mod and Metformin
  2. Max out metformin and A1C above target
    -add to metformin = GLP-1, SGLT-2 INHIBITORS, dpp-4 inhibitors, sulfonylureas, thiazolidinediones, basal insulin
  3. Add injectables
    -1st line: GLP-1 not if A1C>10 or symptom hyperglycemia= insulin
    -2nd: Basal Insulin 10 units per day or 0.1-0.2 units/kg/day-> 3-0-3 method (check fasting sugars for 3 days- average them= if above 130 = increase by 3 units till within goal
    -3rd: prandial insulin- 4 units or 10% basal dose w/ largest meal of day
    -4th: oral meds after adding insulin
    - CONTINUE GLP-1, METFORMIN, SFLT2 INHIB
    -STOP TZDS, SULFONYLUREAS
  4. organization guidelines
    -AACE <6.5 A!C or dual therapy for A1C>7.5, insuline A1C >9
    -ADA <7%, insulin A1C >10%
19
Q

T1DM management

A

INSULIN IS REQUIRED
high cost-> long acting insulin to provide basal componenet and 2 rapid acting insulin
low cost-> two intermed acting insulin and two injecitons of short acting insulin

20
Q

Dosing insulin

A
21
Q

Adjunctive therapy in t1dm

A

Pramlintide- amylin agonist
MOA: mimics action amylin (neurohormone co-secreted from beta cells w/ insulin) reduces glucagon secretion, slows gastric emptying, increases satiety
FIRST NON INSULIN APPROVED FOR T1DM
lowers a1c by 0.6%
AE: GI
in conjunction w/ insulin can cause hypoglycemia

22
Q

Diabetic Ketoacidosis

A

precipitating factor: PNA, UTI, COVID
Presentation: stupor, coma, abdominal pain
Labs:
-serum glucose
-electrolytes
-plasma creatinine
-CBC
-Urinalysis
-serum ketones
-ABG
Dx: HYPERGLYCEMIA + ANION GAP METABOLIC ACIDOSIS + KETONEMIA
Tx:
1. Correction of fluids and electrolytes= Lactated ringers
2. Administer insulin
3. Frequent monitoring - hourly glucose

23
Q

Tx of DKA

A

Pharm 2 (15 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions